TRCT
SLS icon

Tower Research Capital (TRC)’s SELLAS Life Sciences SLS Stock Holding History

Tower Research Capital (TRC)’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137K Sell
9,260
-11,850
-56% -$81.8K ﹤0.01% 1966
2026
Q1 		$89.3K Buy
21,110
+14,636
+226% +$65.5K ﹤0.01% 2273
2025
Q4 		$24.4K Sell
6,474
-6,315
-49% -$12.3K ﹤0.01% 2955
2025
Q3 		$20.6K Sell
12,789
-2,676
-17% -$4.77K ﹤0.01% 3285
2025
Q2 		$33.9K Sell
15,465
-5,424
-26% -$8.32K ﹤0.01% 3310
2025
Q1 		$22.6K Buy
20,889
+15,584
+294% +$18.5K ﹤0.01% 2847
2024
Q4 		$5.52K Buy
5,305
+1,596
+43% +$1.82K ﹤0.01% 4275
2024
Q3 		$4.64K Sell
3,709
-9,922
-73% -$12.1K ﹤0.01% 4464
2024
Q2 		$16.2K Sell
13,631
-7,094
-34% -$9.65K ﹤0.01% 3874
2024
Q1 		$20.9K Buy
20,725
+15,371
+287% +$12.9K ﹤0.01% 2958
2023
Q4 		$5.67K Sell
5,354
-3,660
-41% -$3.96K ﹤0.01% 4816
2023
Q3 		$14.8K Buy
9,014
+1,971
+28% +$3.11K ﹤0.01% 3657
2023
Q2 		$11.1K Sell
7,043
-1,533
-18% -$2.46K ﹤0.01% 4018
2023
Q1 		$12K Buy
8,576
+7,370
+611% +$18.2K ﹤0.01% 4121
2022
Q4 		$3K Sell
1,206
-1,475
-55% -$4.14K ﹤0.01% 5229
2022
Q3 		$5K Sell
2,681
-1,074
-29% -$2.97K ﹤0.01% 5170
2022
Q2 		$8K Buy
3,755
+3,291
+709% +$9.65K ﹤0.01% 4706
2022
Q1 		$3K Sell
464
-430
-48% -$2.52K ﹤0.01% 5413
2021
Q4 		$5K Sell
894
-2,196
-71% -$16.6K ﹤0.01% 5189
2021
Q3 		$28K Buy
3,090
+2,715
+724% +$25.2K ﹤0.01% 3433
2021
Q2 		$4K Sell
375
-979
-72% -$9.55K ﹤0.01% 4834
2021
Q1 		$12K Buy
1,354
+86
+7% +$704 ﹤0.01% 4275
2020
Q4 		$7K Buy
1,268
+808
+176% +$3.23K ﹤0.01% 4504
2020
Q3 		$1K Sell
460
-1,272
-73% -$3.48K ﹤0.01% 4732
2020
Q2 		$5K Buy
+1,732
New +$4.7K ﹤0.01% 4294
2017
Q3 		– Sell
-23
Closed -$20K – 4112
2017
Q2 		$20K Sell
23
-14
-38% -$12.2K ﹤0.01% 1223
2017
Q1 		$34K Buy
37
+30
+429% +$49.7K ﹤0.01% 950
2016
Q4 		$20K Buy
+7
New +$40.7K ﹤0.01% 2150

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tower Research Capital (TRC)'s SLS Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its SELLAS Life Sciences (SLS) stake by 56% in Q2 2026, selling an estimated $81.8K and leaving 9,260 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Tower Research Capital (TRC) first reported a position in SLS in Q4 2016 and has held it in 28 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Tower Research Capital (TRC) held 9,260 shares of SELLAS Life Sciences worth $137K as of Q2 2026.
  • Tower Research Capital (TRC) sold 11,850 SELLAS Life Sciences shares in Q2 2026, an estimated $81.8K.
  • SELLAS Life Sciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1966 holding.
  • Tower Research Capital (TRC) first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 28 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.